Deferasirox Sprinkle Granules and Ethinyl estradiol and norgestrel
Determining the interaction of Deferasirox Sprinkle Granules and Ethinyl estradiol and norgestrel and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Deferasirox may reduce the blood levels and effects of ethinyl estradiol. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4. In healthy volunteers, administration of the CYP450 3A4 probe substrate midazolam in combination with deferasirox resulted in a reduction of midazolam peak concentration by 23% and systemic exposure by 17%. In the clinical setting, this effect may be more pronounced.
MANAGEMENT: Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.
- Skerjanec A, Wang J, Maren K, Rojkjaer L "Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers." J Clin Pharmacol 50 (2010): 205-13
- "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: deferasirox
Brand name: Exjade, Jadenu, Jadenu Sprinkle
Synonyms: Deferasirox
Generic Name: ethinyl estradiol / norgestrel
Brand name: Cryselle 28, Low-Ogestrel, Ogestrel-28, Lo/Ovral-21, Lo/Ovral-28, Ovral, Ovral-28, Low-Ogestrel-21, Ovral-21, Elinest, Cryselle-28, Ogestrel
Synonyms: Norgestrel and Ethinyl Estradiol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Deferasirox Sprinkle Granules-Ethinyl estradiol and segesterone vaginal ring
- Deferasirox Sprinkle Granules-Ethinyl Estradiol, Drospirenone, and Levomefolate
- Deferasirox Sprinkle Granules-Ethinyl estradiol, folic acid, and levonorgestrel
- Deferasirox Sprinkle Granules-Ethinyl Estradiol, Norethindrone, and Ferrous Fumarate
- Deferasirox Sprinkle Granules-Ethiodized oil Injection
- Deferasirox Sprinkle Granules-Ethiodol
- Ethinyl estradiol and norgestrel-Deferasirox Tablets
- Ethinyl estradiol and norgestrel-Deferasirox Tablets For Oral Suspension
- Ethinyl estradiol and norgestrel-Deferiprone
- Ethinyl estradiol and norgestrel-Deferiprone Oral Solution
- Ethinyl estradiol and norgestrel-Deferiprone Tablets
- Ethinyl estradiol and norgestrel-Deferoxamine